ReJoyce Green

ORCID: 0000-0003-1892-0289
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Substance Abuse Treatment and Outcomes
  • Neurotransmitter Receptor Influence on Behavior
  • Smoking Behavior and Cessation
  • Alcohol Consumption and Health Effects
  • Behavioral Health and Interventions
  • Neural and Behavioral Psychology Studies
  • Attention Deficit Hyperactivity Disorder
  • Prenatal Substance Exposure Effects
  • Mental Health Research Topics
  • Cannabis and Cannabinoid Research
  • Alcoholism and Thiamine Deficiency
  • Nicotinic Acetylcholine Receptors Study
  • Gut microbiota and health
  • Homelessness and Social Issues
  • Tryptophan and brain disorders
  • Olfactory and Sensory Function Studies
  • Obesity, Physical Activity, Diet
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Eating Disorders and Behaviors
  • Biochemical Analysis and Sensing Techniques
  • Phytoestrogen effects and research
  • Medication Adherence and Compliance
  • COVID-19 and Mental Health
  • Opioid Use Disorder Treatment
  • Cardiac Health and Mental Health

Medical University of South Carolina
2022-2025

The University of Sydney
2024

University of California, Los Angeles
2015-2023

University of Southern California
2021

Substance use initiation during early adolescence is associated with later development of substance and mental health disorders. This study used various domains to predict initiation, defined as trying any nonprescribed (e.g., alcohol, tobacco, cannabis), by age 12, using a large longitudinal data set.

10.1176/appi.ajp.20230882 article EN American Journal of Psychiatry 2024-05-01

Pharmacological treatments that can concomitantly address cigarette smoking and heavy drinking stand to improve health care delivery for these highly prevalent co-occurring conditions. This superiority trial compared the combination of varenicline naltrexone against alone cessation reduction among heavy-drinking smokers.This was a phase 2 randomized double-blind clinical trial. Participants (N=165) who were daily smokers drank heavily received either mg/day plus 50 or matched placebo pills...

10.1176/appi.ajp.2020.20070993 article EN American Journal of Psychiatry 2021-06-03

This study investigated the associations between prenatal alcohol exposure (PAE), including low and moderate levels of exposure, sleep outcomes in adolescence. is an area that remains understudied despite evidence linking PAE to poor younger children growing recognition harms associated with PAE. Participants were 10,336 adolescents (aged 12-13) from fourth assessment wave Adolescent Brain Cognitive Development Study. Cross-sectional generalised linear mixed models additive used assess...

10.1101/2025.05.14.25327575 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2025-05-14

Background Despite a rich literature on human laboratory paradigms of subjective response (SR) to alcohol, craving for and alcohol self‐administration, few studies have examined the interplay across these 3 constructs. The present study addresses this gap in by examining between SR, craving, self‐administration laboratory. Methods Data were culled from medication (NCT02026011) which heavy drinking participants East Asian ancestry completed 2 double‐blinded counterbalanced experimental...

10.1111/acer.14001 article EN Alcoholism Clinical and Experimental Research 2019-03-12

Abstract Background Alcohol craving is related to problematic alcohol use; therefore, pharmacotherapies that modulate are of interest. N ‐acetylcysteine, an over‐the‐counter antioxidant, a candidate pharmacotherapy for adolescent use with the potential impact craving. Cue‐reactivity paradigms using functional magnetic resonance imaging (fMRI) can identify neural regions implicated in and serve as screening tool novel options. Methods This preliminary study examined effect ‐acetylcysteine on...

10.1111/acer.15402 article EN Alcohol Clinical and Experimental Research 2024-07-03

Abstract Background In a multisite clinical trial, varenicline was effective in reducing drinking both smoking and non‐smoking patients with alcohol dependence. Because use disorder (AUD) is heterogeneous, research aimed at characterizing features associated treatment response could advance personalized pharmacotherapy. The current study examined the utility of multidimensional assessment AUD severity to identify responders treatment. Methods utilized data from 13‐week, Phase 2, randomized,...

10.1111/acer.14674 article EN Alcoholism Clinical and Experimental Research 2021-09-01

Genetic variation in the endogenous opioid system has been identified as 1 potential source of individual variability naltrexone treatment outcomes. The majority pharmacogenetic studies have focused on a particular single nucleotide polymorphism (SNP) mu-opioid receptor gene (OPRM1; rs1799971; commonly known Asn40Asp SNP) Caucasian samples with decidedly mixed results. goal this study was to test effects subjective response alcohol and self-administration individuals East Asian descent. We...

10.1111/acer.13586 article EN Alcoholism Clinical and Experimental Research 2017-12-19

The Penn Alcohol Craving Scale (PACS) is one of the most widely used instruments to measure craving for alcohol. Recent research has suggested that scores on PACS can be as a "stand in" diagnostic criterion alcohol with proposed cutoff >20 indicating "positive" symptom. present study examined convergence between and face-to-face interview assessment craving. A sample non-treatment seeking heavy drinkers (N = 338) enrolled in experimental studies AUD completed well AUD, which included item...

10.1016/j.abrep.2019.100198 article EN cc-by-nc-nd Addictive Behaviors Reports 2019-06-18

: Emerging evidence suggests that opioid receptor antagonists, such as naltrexone, are effective pharmacotherapies for alcohol, opioid, and possibly stimulant use disorders. It is posited naltrexone exerts its effects, in part, by increasing functional connectivity between neural reward circuitry frontal systems implicated executive function. Yet no studies had examined whether function moderates these effects.

10.1080/00952990.2020.1741002 article EN The American Journal of Drug and Alcohol Abuse 2020-04-28
Coming Soon ...